Showing 3191-3200 of 5646 results for "".
- LumiThera Completes Patient Enrollment in LIGHTSITE III Clinical Study to Treat Dry AMDhttps://modernod.com/news/lumithera-completes-patient-enrollment-in-the-lightsite-iii-clinical-study-to-treat-dry-amd/2478882/LumiThera announced it has completed enrollment in its multicenter US clinical study in non-neovascular (dry) age-related macular degeneration (AMD) patients. The randomized, multicenter study, LIGHTSITE III, enrolled the last patient at the Byers Eye Insti
- Kala Pharmaceuticals Announces Eysuvis Now Covered by Express Scriptshttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-express-scripts/2478871/Kala Pharmaceuticals announced that pharmacy benefit manager Express Scripts has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% to its National Preferred, Basic and High Performance Formularies, effective February 5, 2021. Eysuvis is the first and only prescription therapy appr
- Reichert Technologies Debuts New Website Designed to Improve Customer Experiencehttps://modernod.com/news/reichert-technologies-debuts-new-website-designed-to-improve-customer-experience/2478866/Reichert Technologies has announced the launch of a newly redesigned website with an improved user experience. The new website, available at the same address—reichert.com—features a s
- Roche’s Actemra Reduces Deaths in Hospitalized COVID-19 Patients: Studyhttps://modernod.com/news/roches-actemra-reduces-deaths-in-hospitalized-covid-19-patients-study/2478863/New findings released Thursday from the ongoing RECOVERY trial showed that Roche’s arthritis drug Actemra (tocilizumab) significantly reduced mortality among patients hospitalized with severe COVID-19, according to researchers leading the study at the University of Oxford. The intravenous I
- Bausch Health Announces Vyzulta is Now Approved in South Koreahttps://modernod.com/news/bausch-health-announces-vyzulta-is-now-approved-in-south-korea/2478847/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% has received regulatory approval from the Ministry of Food and Drug Safety in South Korea. Vyzulta is indicated for the reduction of IOP in patients w
- Eye Health America Acquires Three Optometric Practices in the Pee Dee Region of South Carolinahttps://modernod.com/news/eye-health-america-acquires-three-optometric-practices-in-the-pee-dee-region-of-south-carolina/2478837/Eye Health America (EHA) has added three optometric practices into its business family: David Hamill, OD, and First Vision Group (FVG); Mark Vinson, OD and Vision Care (VC); and David Johnson, OD and Marlboro Eye Care Associates (MECA). All have been providing eye care in Florence, Marion and Ben
- Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Wet AMDhttps://modernod.com/news/prevent-blindness-and-bausch-lomb-to-launch-year-long-video-series-to-raise-awareness-of-wet-amd/2478818/Bausch + Lomb and Prevent Blindness, the nation’s oldest volunteer eye health non-profit organization, announced they are joining together for the sixth consecutive year during AMD Awareness Month to raise awareness of age-related macular degeneration (AMD). The two organizations will launch a ye
- Eyedaptic Augmented Reality Visual Aid Granted Patent to Further Aid Those With Macular Degeneration and Low Visionhttps://modernod.com/news/eyedaptic-augmented-reality-visual-aid-granted-patent-to-further-aid-those-with-macular-degeneration-and-low-vision/2478789/Eyedaptic announced it was recently granted the first out of nine pending patents. Additionally, Eyedaptic launched an Equity Crowdfunding Campaign to increase awareness and introduce their advanced visual aid solution to an expanding list of stakeholders in the eye care and technology communitie
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. Administered
- EyeSouth Partners Expands Network to Include 28 Doctors in Ohio and Kentucky Through Affiliation with Midwest Eye Centerhttps://modernod.com/news/eyesouth-partners-expands-network-to-include-28-doctors-in-ohio-and-kentucky-through-affiliation-with-midwest-eye-center/2478742/EyeSouth Partners has announced that it has completed an affiliation with Midwest Eye Center (MWEC), representing EyeSouth’s first in the states of Ohio and Kentucky. Terms of the deal were not disclosed. Midwest Eye Center is led by Drs. Mark Cepela, Jean Noll, Faiz Khaja, Saif Jaw